Zoekresultaten - Wan‐Jen Hong

  • Toon 1 - 19 resultaten van 19
Verfijn jouw resultaten
  1. 1
    Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

    Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission door M. Ryan Corces, Wan‐Jen Hong, Irving L. Weissman, Bruno C. Medeiros, Ravindra Majeti

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage

    Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage door Kerri E. Rieger, Wan‐Jen Hong, Virginia Goss Tusher, Jean Y. Tang, Robert Tibshirani, Gilbert Chu

    Gepubliceerd in 2004
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells

    A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells door Andreas Reinisch, Danièl Thomas, M. Ryan Corces, Xiaohua Zhang, Dita Gratzinger, Wan‐Jen Hong, Katharina Schallmoser, Dirk Strunk, Ravindra Majeti

    Gepubliceerd in 2016
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study door Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Gepubliceerd in 2019
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

    Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia door Steven M. Chan, Danièl Thomas, M. Ryan Corces, Seethu Xavy, Suchita Rastogi, Wan‐Jen Hong, Feifei Zhao, Bruno C. Medeiros, David A. Tyvoll, Ravindra Majeti

    Gepubliceerd in 2015
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation

    Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation door Claire Mazumdar, Ying Shen, Seethu Xavy, Feifei Zhao, Andreas Reinisch, Rui Li, M. Ryan Corces, Ryan A. Flynn, Jason D. Buenrostro, Steven M. Chan, Danièl Thomas, Julie L. Koenig, Wan‐Jen Hong, Howard Y. Chang, Ravindra Majeti

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study door Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D. DiNardo

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

    Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia door Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Brian A. Jonas, Martha Arellano, Pamela S. Becker, Olga Frankfurt, Marina Konopleva, Andrew H. Wei, Hagop M. Kantarjian, Tu Xu, Wan-Jen Hong, Brenda Chyla, Jalaja Potluri, Daniel A. Pollyea, Anthony Letai

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands

    Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands door Ignacio Moraga, Gerlinde Wernig, Stephan Wilmes, Vitalina Gryshkova, Christian Richter, Wan‐Jen Hong, Rahul Sinha, Feng Guo, Hyna Fabionar, Tom S. Wehrman, Peter O. Krutzik, Samuel Demharter, Isabelle Plo, Irving L. Weissman, Péter Mináry, Ravindra Majeti, Stefan N. Constantinescu, Jacob Piehler, K. Christopher García

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma door Luciano J. Costa, Faith E. Davies, Gregory Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan‐Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah Al Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji Kumar, Edward A. Stadtmauer

    Gepubliceerd in 2021
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

    A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome door Andrew H. Wei, Jacqueline S. Garcia, Uma Borate, Chun Yew Fong, Maria R. Baer, Florian Nolte, Pierre Péterlin, Joseph G. Jurcic, Guillermo Garcia‐Manero, Wan‐Jen Hong, Uwe Platzbecker, Olatoyosi Odenike, Martin Dunbar, Ying Zhou, Jason G. Harb, Poonam Tanwani, Johannes Wolff, Meagan A. Jacoby

    Gepubliceerd in 2019
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity

    NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity door Rebecca M. Richards, Feifei Zhao, Katherine A. Freitas, Kevin R. Parker, Peng Xu, Amy C. Fan, Elena Sotillo, Mads Daugaard, Htoo Zarni Oo, Jie Liu, Wan‐Jen Hong, Poul H. Sorensen, Howard Y. Chang, Ansuman T. Satpathy, Robbie G. Majzner, Ravindra Majeti, Crystal L. Mackall

    Gepubliceerd in 2021
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

    Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b St... door Jacqueline S. Garcia, Andrew H. Wei, Uma Borate, Chun Yew Fong, Maria R. Baer, Florian Nolte, Joseph G. Jurcic, Meagan A. Jacoby, Wan‐Jen Hong, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, Bo Tong, Leah J. Hogdal, Rajesh Kamalakar, Jessica E. Hutti, Steve Kye, Guillermo Garcia‐Manero

    Gepubliceerd in 2020
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Targeting <scp>BCL</scp>‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma

    Targeting <scp>BCL</scp>‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma door Jonathan L. Kaufman, Cristina Gasparetto, Fredrik Schjesvold, Philippe Moreau, Cyrille Touzeau, Thierry Façon, Lawrence Boise, Yanwen Jiang, Xiaoqing Yang, Fengjiao Dunbar, Deeksha Vishwamitra, Stefanie Unger, Tammy Macartney, John C. Pesko, Yao Yu, Ahmed Hamed Salem, Jeremy A. Ross, Wan‐Jen Hong, Paulo Maciag, James M. Pauff, Shaji Kumar

    Gepubliceerd in 2020
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

    Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies door Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lü, Andrew Kuykendall, David A. Sallman, Manish R. Patel, Don A. Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masárová, Gina Keiffer, Amit Verma, Neha Bhagwat, Min Wang, Andrew S. Moore, Joseph Rager, Diane Heiser, Sunhee Ro, Wan‐Jen Hong, Omar Abdel‐Wahab, Eytan M. Stein

    Gepubliceerd in 2025
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

    Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study door Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop K. Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, Wan-Jen Hong, John Hayslip, Gail J. Roboz

    Gepubliceerd in 2019
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

    A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrom... door Amer M. Zeidan, Daniel A. Pollyea, Jacqueline S. Garcia, Andrew M. Brunner, Fernando Roncolato, Uma Borate, Olatoyosi Odenike, Ashish Bajel, Anne Marie Watson, Katharina S. Götze, Florian Nolte, Peter Tan, Wan‐Jen Hong, Martin Dunbar, Ying Zhou, Lori A. Gressick, William B. Ainsworth, Jason G. Harb, Ahmed Hamed Salem, John Hayslip, Ronan Swords, Guillermo Garcia‐Manero

    Gepubliceerd in 2019
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

    Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial door Naval Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion Ott, Wan‐Jen Hong, Marina Konopleva, Michael Andreeff

    Gepubliceerd in 2022
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

    Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia door Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Jacqueline S. Garcia, Andrew H. Wei, Marina Konopleva, Hartmut Döhner, Anthony Letai, Pierre Fenaux, Elizabeth A. Koller, Violaine Havelange, Brian Leber, Jordi Esteve, Jianxiang Wang, Vlatko Pejša, Roman Hájek, Kimmo Porkka, Árpád Illés, David Lavie, Roberto M. Lemoli, Kazuhito Yamamoto, Sung‐Soo Yoon, Jun‐Ho Jang, Su‐Peng Yeh, Mehmet Turgut, Wan‐Jen Hong, Ying Zhou, Jalaja Potluri, Keith W. Pratz

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: